RecruitingNot ApplicableNCT06000787

MCT for the Harvard/UCSF ROBIN Center

Molecular Characterization Trial for the Harvard/UCSF ROBIN Center: Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science


Sponsor

Brigham and Women's Hospital

Enrollment

47 participants

Start Date

Sep 19, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the deep annotation of these research biospecimens with elements that complement each other to provide a holistic, detailed view of each patient. Annotated elements include those used in the past such as clinical and biological features but extend to factors we have so far neglected but must incorporate in the future such as dosimetry (precise anatomical measurement of radiation dose), artificial intelligence, computational biology, and natural language processing.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study explores whether a metabolic therapy (a special high-fat, low-carbohydrate diet) can support children and young adults enrolled in specific pediatric cancer trials — including trials for brain tumors (diffuse midline glioma) and high-risk neuroblastoma. **You may be eligible if...** - You are already enrolled in one of several specific pediatric oncology clinical trials (including studies for diffuse midline glioma, neuroblastoma, medulloblastoma, or other brain tumors) - You meet the eligibility criteria of the specific parent trial you are enrolled in **You may NOT be eligible if...** - You are not enrolled in one of the specific listed cancer trials - You do not meet the requirements of the parent trial (such as age, diagnosis, or performance status criteria) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONExternal beam radiotherapy

Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.

RADIATION131I-Metaiodobenzylguanidine (MIBG)

Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.


Locations(2)

University of California, San Francisco

San Francisco, California, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06000787


Related Trials